RedHill Biopharma Ltd. RDHL

Company Overview

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of therapies primarily targeting gastrointestinal diseases, infectious diseases, and oncology-related conditions. The company operates within the biotechnology and pharmaceutical industries and has historically concentrated on late-stage clinical development, drug commercialization, and repurposed therapeutics. Its revenue has been derived from product sales, licensing arrangements, collaboration agreements, and, in certain periods, milestone-related payments tied to development programs.

The company’s principal products and pipeline assets have included gastrointestinal-focused therapies such as Talicia for Helicobacter pylori infection and Movantik commercialization rights in selected territories, alongside investigational programs targeting COVID-19, inflammatory conditions, and other infectious diseases. RedHill was founded in Israel in 2009 and is headquartered in Tel Aviv, with operations and commercial activities extending into the United States. Over time, the company evolved from a development-stage biotechnology enterprise into a commercially oriented specialty pharmaceutical company through acquisitions, licensing agreements, and commercialization partnerships centered on U.S. specialty markets.

Business Operations

RedHill Biopharma organizes its activities around commercial pharmaceutical operations and clinical-stage drug development. Its commercial business has centered on gastrointestinal therapies, including Talicia and previously promoted products such as Aemcolo and Movantik in designated markets. The company has also maintained development programs involving investigational assets including opaganib, RHB-204, and RHB-107, targeting infectious diseases, pulmonary conditions, and oncology-related indications. Revenue generation has historically depended on prescription sales, commercialization partnerships, licensing arrangements, and strategic collaborations.

Operationally, the company has maintained activities in both North America and Israel, with commercialization efforts concentrated largely in the U.S. market. RedHill has controlled intellectual property portfolios tied to formulation technologies, combination therapies, and orphan or specialty drug candidates. Strategic collaborations and licensing arrangements have involved pharmaceutical manufacturers, distributors, and research institutions. Public filings have also referenced relationships involving products acquired or licensed from external pharmaceutical companies, including commercialization rights associated with Movantik and other specialty assets. Certain operational details and revenue contributions have varied materially over time due to restructuring initiatives, financing constraints, and portfolio prioritization disclosed in public filings.

Strategic Position & Investments

RedHill’s strategic direction has focused on specialty gastrointestinal therapeutics and the advancement of repurposed or late-stage drug candidates intended to address unmet medical needs. The company has pursued growth through targeted acquisitions, licensing agreements, and internal clinical development. One notable transaction included the acquisition of U.S. rights associated with gastrointestinal products intended to strengthen its commercial infrastructure and physician reach in gastroenterology markets. RedHill has also invested in clinical-stage infectious disease and inflammatory programs, including opaganib, which gained visibility during COVID-19-related development efforts.

The company’s broader strategy has emphasized leveraging existing clinical data and regulatory pathways to potentially accelerate commercialization timelines and reduce development risk relative to early-stage biotechnology models. RedHill has maintained interests in emerging therapeutic areas involving host-directed antiviral therapies, microbiome-related gastrointestinal treatment approaches, and inflammatory disease mechanisms. Public disclosures indicate continued evaluation of financing alternatives, portfolio prioritization, and strategic partnerships to support operations and clinical advancement. Some reported development timelines and commercialization expectations have changed over successive reporting periods, and certain future initiatives remain subject to regulatory outcomes and capital availability.

Geographic Footprint

RedHill Biopharma is headquartered in Tel Aviv, Israel, with substantial historical operational and commercial activity in the United States, particularly through its U.S.-focused specialty pharmaceutical business. The company’s commercial footprint has primarily targeted the U.S. gastroenterology market, where physician-directed sales and specialty product distribution represented key operational priorities.

Beyond its core U.S. and Israeli presence, RedHill has pursued international licensing, research collaborations, and development activities involving partners in Europe, Asia, and other global markets. Clinical trials and regulatory interactions have involved multiple jurisdictions, reflecting the company’s effort to position certain investigational assets for broader international opportunities. However, the scale and continuity of international operations have fluctuated over time in line with financing conditions, product commercialization status, and strategic restructuring initiatives disclosed in company filings.

Leadership & Governance

RedHill Biopharma was co-founded by Dror Ben-Asher, who has played a central role in shaping the company’s strategic direction and financing activities since inception. The company’s leadership approach has emphasized specialty pharmaceutical commercialization combined with selective late-stage development opportunities in gastrointestinal and infectious disease markets. Public corporate communications and filings have consistently highlighted a strategy centered on maximizing the value of differentiated therapeutic assets through commercialization, partnerships, and regulatory advancement.

Key executives and leadership figures have included:

• Dror Ben-Asher – Chairman of the Board
• Gilead Raday – Chief Executive Officer
• Micha Benozio – Chief Financial Officer
• Dr. Adi Frish – Chief Corporate and Business Development Officer
• Guy Goldberg – Chief Business Officer

Leadership composition and executive roles have changed periodically as part of broader operational restructuring and strategic realignment efforts. Public disclosures in SEC filings and investor communications indicate ongoing emphasis on financial discipline, commercialization execution, and advancement of selected clinical-stage assets.